Bloomberg the Company

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Follow Us

Industry Products

  • Exchange: Venture
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

Kane Biotech Inc

+ Add to Watchlist

KNE:CN

0.0450 CAD 0.00000.00%

As of 14:26:02 ET on 01/26/2015.

Snapshot for Kane Biotech Inc (KNE)

Open: 0.0450 Day's Range: 0.0450 - 0.0450 Volume: 185,000
Previous Close: 0.0450 52wk Range: 0.0250 - 0.1250 1-Yr Rtn: -59.09%

Stock Chart for KNE

No chart data available.
  • KNE:CN 0.0450
  • 1D
  • 1M
  • 1Y
0.0450
Interactive KNE Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for KNE

Current P/E Ratio (ttm) -
Estimated P/E(-) -
Relative P/E vs. SPTSX -
Earnings Per Share (ttm) -0.0110
Est. EPS -
Est. PEG Ratio -
Market Cap (M CAD) 3.70
Shares Outstanding (M) 82.27
30 Day Average Volume 123,848
Price/Book (mrq) 6.5217
Price/Sale (ttm) 20.0296
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 04/06/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for KNE

  • Revenue
  • Net Income (M/CAD)
  • Profit Margin (%)

Company Profile & Key Executives for KNE

Kane Biotech Inc. is involved in the research and development of products to prevent and disperse bacterial biofilms. The Company's technology includes targets, methods, and processes involved in the formation of biofilms. Kane's technology has potential to improve the ability to prevent and/or destroy biofilms, in several medical and industrial applications.

Gordon FroehlichPresident/CEOMark MatthewsonChief Financial Officer
More Company Profile & Key Executives for KNE

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil